uniQure (NASDAQ:QURE) Trading Down 6.5% Following Insider Selling

Shares of uniQure N.V. (NASDAQ:QURE - Get Free Report) fell 6.5% on Friday after an insider sold shares in the company. The company traded as low as $13.99 and last traded at $14.11. 1,117,485 shares changed hands during mid-day trading, a decline of 42% from the average session volume of 1,932,323 shares. The stock had previously closed at $15.10.

Specifically, insider Jeannette Potts sold 4,670 shares of uniQure stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $15.14, for a total value of $70,703.80. Following the sale, the insider now owns 115,073 shares of the company's stock, valued at approximately $1,742,205.22. The trade was a 3.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on QURE. Chardan Capital restated a "buy" rating and issued a $38.00 price target on shares of uniQure in a research note on Friday, May 30th. Cantor Fitzgerald raised uniQure to a "strong-buy" rating in a report on Monday, May 19th. Wells Fargo & Company cut their price target on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a report on Friday, February 28th. Guggenheim reiterated a "buy" rating and issued a $28.00 price objective on shares of uniQure in a research note on Monday, May 12th. Finally, Wall Street Zen cut shares of uniQure from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, uniQure presently has an average rating of "Moderate Buy" and an average price target of $37.82.

uniQure Trading Down 1.8%

The business's fifty day moving average price is $14.20 and its 200 day moving average price is $13.94. The company has a quick ratio of 11.99, a current ratio of 11.99 and a debt-to-equity ratio of 1.53. The firm has a market capitalization of $764.18 million, a PE ratio of -3.18 and a beta of 0.08.

uniQure (NASDAQ:QURE - Get Free Report) last announced its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.25. The firm had revenue of $1.57 million for the quarter, compared to analyst estimates of $5.93 million. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. As a group, analysts expect that uniQure N.V. will post -3.75 EPS for the current fiscal year.

Institutional Investors Weigh In On uniQure

Hedge funds have recently made changes to their positions in the business. Oppenheimer & Co. Inc. purchased a new position in uniQure during the fourth quarter worth about $320,000. Raymond James Financial Inc. acquired a new stake in uniQure during the 4th quarter worth approximately $1,951,000. Monaco Asset Management SAM purchased a new position in shares of uniQure in the 4th quarter valued at $2,414,000. Twin Tree Management LP purchased a new position in shares of uniQure in the 4th quarter valued at $77,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of uniQure by 14.7% during the 4th quarter. JPMorgan Chase & Co. now owns 453,784 shares of the biotechnology company's stock valued at $8,014,000 after acquiring an additional 58,246 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.